Dr. Sharon Benzeno has served as Adaptive Biotechnologies' Chief Commercial Officer, Immune Medicine since April 2022 and leads the Drug Discovery group. She previously served as Chief Business Development Officer (2020-2022), Senior Vice President, Drug Discovery (2018-2020) and in business development roles of ascending responsibility after joining Adaptive in September 2014. Before Adaptive she was a Senior Director at Elsevier Inc., a Senior Manager in the oncology business unit at Capgemini SE, and held oncology alliance and scientific management roles at AstraZeneca plc. Dr. Benzeno holds a PhD in Biomedical Sciences from New York University School of Medicine, an MBA in Finance and Leadership from NYU's Stern School of Business and a BA in Biochemistry from NYU, and completed a postdoctoral fellowship in cancer biology at the University of Pennsylvania Abramson Cancer Center.